Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

← catalyst calendar

NCT04649359 · results posted

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
187actual
Sites
40
Countries
Australia, Canada, France +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-02-02actualWhen the study began enrolling
Primary completion2022-06-17actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-12-31estimatedThe whole study's end, after follow-up
First posted2020-12-02actualWhen this record first appeared on the registry
Results posted2023-10-25actualWhen the sponsor posted results to the registry
Record updated2026-05-19actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Multiple Myeloma

Intervention

  • Drug: Elranatamab (PF-06863135)

Primary outcome

what the primary-completion date above is the date OF
Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria
measured From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2023-03-22 · 1.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-10-26 · 2.8 MB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed